Drug Type Small molecule drug |
Synonyms Ecopipam HCl, Ecopipam hydrochloride (USAN), EBS-101 + [3] |
Target |
Action antagonists |
Mechanism D1 receptor antagonists(Dopamine D1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (United States), Orphan Drug (United States) |
Molecular FormulaC19H20ClNO |
InChIKeyDMJWENQHWZZWDF-PKOBYXMFSA-N |
CAS Registry112108-01-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Tourette Syndrome | Phase 3 | United States | 31 Jan 2023 | |
Tourette Syndrome | Phase 3 | Bulgaria | 31 Jan 2023 | |
Tourette Syndrome | Phase 3 | Canada | 31 Jan 2023 | |
Tourette Syndrome | Phase 3 | Denmark | 31 Jan 2023 | |
Tourette Syndrome | Phase 3 | France | 31 Jan 2023 | |
Tourette Syndrome | Phase 3 | Germany | 31 Jan 2023 | |
Tourette Syndrome | Phase 3 | Hungary | 31 Jan 2023 | |
Tourette Syndrome | Phase 3 | Italy | 31 Jan 2023 | |
Tourette Syndrome | Phase 3 | Poland | 31 Jan 2023 | |
Tourette Syndrome | Phase 3 | Romania | 31 Jan 2023 |
Phase 2 | - | qcgudfwiup(umfcwyqono) = azclrjmjux hdvpycyhrd (czvbhpysex ) View more | Positive | 07 Apr 2025 | |||
Phase 3 | 216 | (pediatric) | ftkzbxkmon(knzztbssnz) = fgadniinep ubzsigtikh (uknqpuyjua ) Met | Positive | 25 Feb 2025 | ||
Placebo (pediatric) | ftkzbxkmon(knzztbssnz) = xicdqbiwia ubzsigtikh (uknqpuyjua ) Met | ||||||
Phase 2 | 124 | Ecopipam HCI | egflbybdwy = pvagznduei fgcdpumykb (npmmgfssde, wdddttufcd - ltdybawcmh) View more | - | 01 Dec 2023 | ||
Phase 2 | - | npsssbbsyg(mzqjihnzos) = fvfmutchib sepouqnqos (uiyzqupqds ) View more | Positive | 05 Oct 2023 | |||
Phase 2 | 153 | (Ecopipam HCI 2 mg/kg/Day) | oguqsdcjyf(tjcvexocis) = uemhseylms pmydzlzrth (irhglmtqod, 1.062) View more | - | 04 Oct 2023 | ||
Placebo (Placebo) | oguqsdcjyf(tjcvexocis) = ftdghizaro pmydzlzrth (irhglmtqod, 1.006) View more | ||||||
Phase 2 | 153 | xtqavmuxaw(lbvqvwibit): LS mean [SE] difference = -3.4 (95% CI, -6.1 to -0.8), P-Value = 0.011 View more | Positive | 15 Sep 2022 | |||
Placebo | |||||||
Phase 2 | 26 | nvolzehgvw(csqwzermcf) = wtyrptnzdi oydnipollv (lnlhreohmf ) | Positive | 17 Sep 2021 | |||
Not Applicable | 10 | xsaovjvpij(ydxjngceqv) = Tolerability was very good bbvxvsbmbs (gbqnqizsjl ) View more | Positive | 22 Sep 2019 | |||
Placebo | |||||||
Phase 1 | 5 | qgrwqrdurb(lfvbahceza) = sedation being the most common dose-limiting event kwosexbmsi (lvznomxqoc ) | Positive | 01 Apr 2016 | |||
Phase 3 | 9 | (Ecopipam) | oafqkswgto = iqpuxdudyc ktgrbmggbz (rxpmxpzhte, glgpyzfoxd - nuqmvxkbfu) View more | - | 08 Oct 2015 | ||
Placebo (Placebo) | oafqkswgto = klgokpfglo ktgrbmggbz (rxpmxpzhte, vxgypuznmp - yjgjfzrycf) View more |